Biogen(US:BIIB) Ge Long Hui·2026-01-15 09:53Group 1 - The core viewpoint of the article is that Goldman Sachs has upgraded Biogen Inc. (BIIB.US) to a "Buy" rating with a target price of $225 after meeting with the company's management, who emphasized a cultural shift towards research and development and cost control to counteract the decline in its multiple sclerosis business and drive growth [1][1][1] - Goldman Sachs believes that Biogen is poised for a turning point this year, driven by catalysts in its research pipeline and the Leqembi product, along with strict cost control and a strategic focus on developing early-stage rare disease and/or immunology assets [1][1][1] Group 2 - Biogen's pre-market stock price increased by 1.26% to $171.45, following the positive news from Goldman Sachs [1][1] - The company's recent stock performance shows a closing price of $169.31, down 5.04%, with a trading volume of 3.6359 million shares [1][1] - Biogen's total market capitalization is approximately $24.838 billion, with a price-to-earnings ratio of 15.14 and a price-to-book ratio of 1.364 [1][1]